Precipio, Inc. Price & Performance (PRPO)

Several biotech firms, including Opthea and Charles River Laboratories, have announced substantial workforce reductions and restructuring moves in the past week. Companies cite the need to conserve cash, streamline operations, and prioritize lead drug candidates as driving factors. These actions reflect broader pressures on the sector to maintain financial stability and focus on core assets.1

A wave of corporate actions has hit small-cap companies, with multiple firms enacting reverse stock splits or facing delistings. Notably, KWESST Micro Systems and Twin Vee PowerCats executed significant reverse splits, while several ETFs and biotechs were delisted pending liquidation. These moves underscore ongoing volatility and restructuring in niche market segments.2

Telesis Bio has secured up to $21 million to accelerate the adoption of its Gibson SOLA technology for rapid DNA and mRNA synthesis. The funding aims to boost the company’s presence in the synthetic biology market, enabling faster therapeutic discovery through automated, on-site DNA foundries.3